Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBIOSS-BALANCED: Albumin Replacement and Balanced Crystalloids in Septic Shock
2018-001582-16Phase 3Completed
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of albumin (human) in septic shock and acute kidney failure (AKF) (4 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoints: All-cause 90-day mortality (Aim 1) and Composite of 90-day mortality and/or incidence of acute kidney injury (Aim 2). Started Mar 2019; status: completed.
02
Drugs
albumin (human)
03
Conditions
septic shockacute kidney failure (AKF)
Beyond the preview
Go deeper on 2018-001582-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001582-16.